atugen presenting at Sachs-Bloomberg in Boston. Sirna still owns a piece of atugen, though not sure how much anymore.
Cheers,
Thomas
Sachs-Bloomberg Global Biotech Forum for Investing & Partnering 2004 Participant Profiles
BIOWIRE2K
Global Biotech Investor Forum 2004
BOSTON--(BUSINESS WIRE)--March 17, 2004--The Sachs-Bloomberg Annual Global Biotech Forum for Investing & Partnering takes place April 1-2, 2004, at the Fairmont Copley Plaza in Boston. For in-depth information about the event, visit sachsforum.com.
Below are profiles from Global Biotech Forum presenters. Breaking news releases are available at tradeshownews.com, Business Wire's trade show and conference news resource. Business Wire is the official news wire service for the Sachs-Bloomberg Global Biotech Forum for Investing & Partnering.
<SNIP>
Company: atugen AG
Media Contact: Thomas Christely
Phone:+49 30 9489 2800
E-mail: christely@atugen.com
Company URL: www.atugen.com
Product description:
--siRNA therapeutic candidates in Diabetes and Oncology
--Pipeline of proprietary novel and functionally validated cancer
targets
--Largest set of KnockDown technologies (low toxic GeneBlocs
antisense molecules, stabilized synthetic siRNA)
--Superior delivery reagents transfecting almost all cell types
(transfection rate greater than 95%)
Company description: atugen AG is a technology leader in
functional gene silencing. The company is based in Berlin, Germany,
and currently has about 40 employees. atugen's in-house drug
development programs mainly focus on the generation of novel siRNA
therapeutics. Here, the company exploits its expertise in
oligonucleotide delivery and its recently discovered,
chemically-stabilized, proprietary siRNA structures. With its contract
research business , the company offers its expertise in target
validation and drug discovery to biopharmaceutical customers and
partners through research alliances and on a fee-for-service basis. |
